Bio-Reference Laboratories COO Sells $588,000 in Stock (BRLI)
Bio-Reference Laboratories (NASDAQ:BRLI) COO Howard Dubinett sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $29.40, for a total value of $588,000.00. Following the sale, the chief operating officer now directly owns 345,138 shares of the company’s stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at William Blair downgraded shares of Bio-Reference Laboratories (NASDAQ:BRLI) from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, July 10th.
Bio-Reference Laboratories (NASDAQ:BRLI) traded down 0.51% on Monday, hitting $29.36. 136,293 shares of the company’s stock traded hands. Bio-Reference Laboratories has a 52 week low of $23.36 and a 52 week high of $32.86. The stock’s 50-day moving average is $27.56 and its 200-day moving average is $27.47. The company has a market cap of $812.5 million and a price-to-earnings ratio of 17.26.
Bio-Reference Laboratories (NASDAQ:BRLI) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.51 by $0.02. The company had revenue of $185.40 million for the quarter, compared to the consensus estimate of $183.50 million. During the same quarter last year, the company posted $0.45 earnings per share. Bio-Reference Laboratories’s revenue was up 7.6% compared to the same quarter last year. Analysts expect that Bio-Reference Laboratories will post $1.80 EPS for the current fiscal year.
Bio-Reference Laboratories, Inc (NASDAQ:BRLI) is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.